Clinical Features, Diagnosis, Treatment, and Prognosis of Heparin-Induced Bullous Hemorrhagic Dermatosis

Table 2

Heparin administration regimen in 72 patients with HBHD.

Parameters		Result
Heparin type	Enoxaparin	53 (73.6%)
	Tinzaparin	4 (5.6%)
	Bemiparin	1 (1.4%)
	Dalteparin	1 (1.4%)
	Reviparin	1 (1.4%)
	UFH	10 (13.9%)
	LMWH	2 (2.8%)
Drug delivery route	Intravenously	9 (12.5%)
	Subcutaneously	63 (87.5%)
Time to lesions (70)^a	Days	7 (0.25, 270)^b
Daily dose		41 (56.9%)
Previous heparin treatment		9 (12.5%)

UFH, unfractionated heparin; LMWH, low molecular weight heparin. ^aRepresents the number of patients out of 72 for whom information regarding this particular parameter was provided. ^bMedian (minimum-maximum).